Rapport Therapeutics, Inc.
RAPP
$11.44
$0.0550.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 107.00% | -- | -- | 520.19% | |
| Total Receivables | -- | -- | -- | -- | |
| Inventory | -- | -- | -- | -- | |
| Prepaid Expenses | -80.00% | -- | -- | -- | |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | |
| Other Current Assets | 122.91% | -- | -- | -- | |
| Total Current Assets | 105.34% | -- | -- | -- | |
|
|
|||||
| Total Current Assets | 105.34% | -- | -- | -- | |
| Net Property, Plant & Equipment | 24.28% | -- | -- | -- | |
| Long-term Investments | -- | -- | -- | -- | |
| Goodwill | -- | -- | -- | -- | |
| Total Other Intangibles | -- | -- | -- | -- | |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | |
| Total Other Assets | -70.96% | -- | -- | -- | |
| Total Assets | 102.63% | -- | -- | -- | |
|
|
|||||
| Total Accounts Payable | -21.90% | -- | -- | -- | |
| Total Accrued Expenses | 7.90% | -- | -- | -- | |
| Short-term Debt | -- | -- | -- | -- | |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | |
| Finance Division Debt Current | 10.00% | -- | -- | -- | |
| Total Finance Division Other Current Liabilities | -- | -- | -- | -- | |
| Total Other Current Liabilities | -- | -- | -- | -- | |
| Total Current Liabilities | -0.41% | -- | -- | -- | |
|
|
|||||
| Total Current Liabilities | -0.41% | -- | -- | -- | |
| Long-Term Debt | -- | -- | -- | -- | |
| Short-term Debt | -- | -- | -- | -- | |
| Capital Leases | -49.93% | -- | -- | -- | |
| Finance Division Debt Non Current | -- | -- | -- | -- | |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | |
| Total Other Liabilities | -- | -- | -- | -- | |
| Total Liabilities | -34.35% | -- | -- | -- | |
|
|
|||||
| Common Stock & APIC | 2,070.17% | -- | -- | -- | |
| Retained Earnings | -172.34% | -- | -- | -- | |
| Treasury Stock & Other | -13,150.00% | -- | -- | -- | |
| Total Common Equity | 1,291.49% | -- | -- | -293.89% | |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | |
| Preferred Stock Convertible | -- | -- | -- | -- | |
| Preferred Stock, Others | -- | -- | -- | -- | |
| Total Preferred Equity | -- | -- | -- | 693.92% | |
|
|
|||||
| Total Common Equity | 1,291.49% | -- | -- | -293.89% | |
| Total Preferred Equity | -- | -- | -- | 693.92% | |
| Total Minority Interest | -- | -- | -- | -- | |
| Total Equity | 116.70% | -- | -- | 900.29% | |
|
|
|||||